애나벡스 라이프 사이언시즈(AVXL)는 NASDAQ에 상장된 Healthcare · Biotechnology 기업입니다. 현재가 $2.42 (+0.41%), 시가총액 $0.31B, 52주 최저~최고 $2.74 ~ $13.41.
Anavex Life Sciences Corp. operates as a biopharmaceutical company. It engages in developing innovative treatments for Alzheimer's disease, Parkinson's disease, schizophrenia, neurodevelopmental, neurodegenerative, and rare diseases, including Rett syndrome, and other central nervous system (CNS) disorders, pain, and various types of cancer . Its lead drug candidate, ANAVEX 2-73 (blarcamesine), has completed a Phase 2a and a Phase 2b/3 clinical trial for Alzheimer's disease; a Phase 2 proof-of-concept study in Parkinson's disease dementia; and a Phase 2 and a Phase 3 study in adult patients and one Phase 2/3 study in pediatric patients with Rett syndrome. Its ANAVEX 2-73 is an orally availab
애나벡스 라이프 사이언시즈의 재무제표, 목표주가, 기관투자자(13F) 보유 현황, 관련 뉴스는 BlackAll Trade에서 실시간으로 확인할 수 있습니다.
애나벡스 라이프 사이언시즈의 현재 주가는 $2.42 (+0.41%)입니다. BlackAll Trade에서 실시간 시세와 차트를 확인할 수 있습니다.
애나벡스 라이프 사이언시즈의 시가총액은 약 $0.31B입니다.
Anavex Life Sciences Corp. operates as a biopharmaceutical company. It engages in developing innovative treatments for Alzheimer's disease, Parkinson's disease, schizophrenia, neurodevelopmental, neur